In contrast, pioglitazone, SGLT2 inhibitors, and GLP-1 receptor agonists have shown strong effectiveness in reducing liver fat and resolving MASH, positioning them as promising treatments for MASLD [16]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatohepatitis.